Enveric Biosciences Gestione

Gestione criteri di controllo 3/4

Enveric Biosciences Il CEO è Joseph Tucker, nominato in Sep2021, e ha un mandato di 3.17 anni. la retribuzione annua totale è $ 577.07K, composta da 78.1% di stipendio e 21.9% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.33% delle azioni della società, per un valore di € 8.99K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 3.2 anni e 2.3 anni.

Informazioni chiave

Joseph Tucker

Amministratore delegato

US$577.1k

Compenso totale

Percentuale dello stipendio del CEO	78.1%
Mandato del CEO	3.2yrs
Proprietà del CEO	0.3%
Durata media del management	3.2yrs
Durata media del Consiglio di amministrazione	2.3yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Joseph Tucker rispetto agli utili di Enveric Biosciences?
Data	Compenso totale	Stipendio	Guadagni aziendali
Sep 30 2024	n/a	n/a	-US$10m
Jun 30 2024	n/a	n/a	-US$11m
Mar 31 2024	n/a	n/a	-US$15m
Dec 31 2023	US$577k	US$451k	-US$17m
Sep 30 2023	n/a	n/a	-US$23m
Jun 30 2023	n/a	n/a	-US$23m
Mar 31 2023	n/a	n/a	-US$19m
Dec 31 2022	US$826k	US$362k	-US$19m
Sep 30 2022	n/a	n/a	-US$52m
Jun 30 2022	n/a	n/a	-US$52m
Mar 31 2022	n/a	n/a	-US$50m
Dec 31 2021	US$3m	US$92k	-US$49m

Compensazione vs Mercato: La retribuzione totale di Joseph ($USD 577.07K ) è circa la media per le aziende di dimensioni simili nel mercato German ($USD 474.54K ).

Compensazione vs guadagni: La retribuzione di Joseph è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Joseph Tucker (55 yo)

3.2yrs

Mandato

US$577,065

Compensazione

Dr. Joseph Tucker, Ph D., has been a Director of Enveric Biosciences, Inc. since September 16, 2021. Dr. Tucker has been the Chief Executive Officer of Enveric Biosciences, Inc. since September 16, 2021.D...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Joseph Tucker	CEO & Director	3.2yrs	US$577.07k	0.33% € 9.0k
Kevin Coveney	Chief Financial Officer	1.7yrs	US$435.31k	0.074% € 2.0k
Peter Facchini	Chief Innovation Officer	3.2yrs	US$282.06k	0.22% € 6.1k

3.2yrs

Durata media

60yo

Età media

Gestione esperta: Il team dirigenziale di SLZA è considerato esperto (durata media dell'incarico 3.2 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Joseph Tucker	CEO & Director	3.2yrs	US$577.07k	0.33% € 9.0k
Michael Webb	Independent Chairman of the Board	2.4yrs	US$175.00k	0.54% € 14.7k
Sheila DeWitt	Independent Director	less than a year	Nessun dato	0.31% € 8.6k
Stephen Stahl	Member of Scientific Advisory Board	2.3yrs	Nessun dato	Nessun dato
Frank Pasqualone	Independent Director	2.3yrs	US$57.50k	0.55% € 15.0k
Maurizio Fava	Chairman of Scientific Advisory Board	2.3yrs	Nessun dato	Nessun dato
Michael Liebowitz	Member of Scientific Advisory Board	2.3yrs	Nessun dato	Nessun dato
John Krystal	Member of Scientific Advisory Board	2.3yrs	Nessun dato	Nessun dato
Marcus Schabacker	Independent Non-Employee Director	3.9yrs	US$52.00k	0.54% € 14.8k
George Kegler	Independent Non-Employee Director	3.9yrs	US$59.00k	0.54% € 14.8k

2.3yrs

Durata media

64yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di SLZA non è considerato esperto (durata media del mandato 2.3 anni), il che suggerisce un nuovo consiglio.

Enveric Biosciences Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

High number of new and inexperienced directors

Enveric Biosciences, Inc., Annual General Meeting, May 28, 2024

Enveric Biosciences, Inc., Annual General Meeting, Nov 02, 2023

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

Recent updates

Enveric Biosciences Announces Completion of Preclinical Pharmacokinetic Studies of EB-003 Support Oral Bioavailability, Demonstrate Brain Penetration, and Show No Evidence of Hallucination-Like Behavior

The Listing Qualifications Department of the Nasdaq Stock Market Issues A Determination to Enveric Biosciences

The Listing Qualifications Department of the Nasdaq Stock Market Issues A Determination to Enveric Biosciences

New major risk - Financial position

Enveric Biosciences Announces Positive Pharmacology and Safety Data for Lead Product, EB-003

New major risk - Financial position

Enveric Biosciences Announces Preclinical Results Confirming Potential of EB-003 to Be Dosed Orally

New major risk - Share price stability

Enveric Biosciences Regains Compliance with the Minimum Stockholders’ Equity Requirement for Continued Listing on the Nasdaq Capital Market Pursuant to Nasdaq Listing Rule 5550(b)(1)

Enveric Biosciences Receives Notification Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market Pursuant to Nasdaq Marketplace Rule 5550(a)(2)

New major risk - Financial position

High number of new and inexperienced directors

Enveric Biosciences, Inc., Annual General Meeting, May 28, 2024

New major risk - Shareholder dilution

Enveric Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $0.322453 million.

Enveric Biosciences Unveils Library of Preclinical Compounds Across Multiple Distinct Molecule Classes Targeting Mental Health Disorders

Enveric Biosciences Receives Notice from the Nasdaq Stock Market

New major risk - Share price stability

Enveric Biosciences Selects EB-003 as Lead Drug Candidate from EVM301 Series

Enveric Biosciences Selects Development Candidates from Evm301 Series Based on Potential to Minimize or Eliminate the Hallucinogenic Effect of Psychedelic-Derived Compounds

Enveric Biosciences Announces Manuscript Describing the Development of Lead Product Candidate, EB-373, to be Featured on the Cover of the Journal of Medicinal Chemistry

Enveric Biosciences Announces Manuscript Describing the Development of Lead Product Candidate, EB-373, to be Featured on the Cover of the Journal of Medicinal Chemistry

Enveric Biosciences Receives a Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Enveric Biosciences Initiates GLP Toxicology & Safety Pharmacology Studies for Lead Candidate EB-373

Enveric Biosciences, Inc., Annual General Meeting, Nov 02, 2023

Enveric Biosciences Completes Manufacturing of EB-373 to Supply Drug Material for Completion of Preclinical Program

High number of new and inexperienced directors

Enveric Biosciences, Inc. Reports Positive Results from Preclinical Studies Supporting Metabolic Profile of Lead Candidate EB-373

Enveric Biosciences Reports Positive Results from Animal Studies Demonstrating Oral Bioavailability and Well Tolerated Side Effect Profile for EB-373

Enveric Biosciences, Inc. Announces Development of Phase 1-Ready Formulation for EB-373 and Initiation of Scaled Up Manufacturing

Enveric Biosciences, Inc. Announces Manuscript Detailing the Development of Novel Psilocin Prodrugs for the Treatment of Anxiety and Other Mental Health Disorders

Enveric Biosciences, Inc. Receives Notice of Allowance from Uspto for Novel Prodrug of Psilocin

High number of new and inexperienced directors

High number of new and inexperienced directors

Enveric Biosciences, Inc. Advances Lead Candidate for the Treatment of Anxiety Disorders to IND-Enabling Studies

Enveric Biosciences, Inc., Annual General Meeting, Oct 28, 2022

Enveric Biosciences, Inc. Appoints Robert Dickey IV as Chief Financial Officer

Enveric Biosciences, Inc. Regains Compliance with Listing Rule 5550(a)(2) Letter from the Listing Qualifications Department of Nasdaq

Enveric Biosciences, Inc. Appoints New Independent Directors

Enveric Biosciences, Inc. announced that it expects to receive $5 million in funding

Enveric Biosciences Announces Formation of Scientific Advisory Board to Drive Further Growth of Next-Generation Mental Health Medicines

Enveric Biosciences, Inc. Announces Appointment of Frank Pasqualone to the Board of Directors

Enveric Biosciences Announces Management Appointments

High number of new and inexperienced directors

Enveric Biosciences, Inc. Expands Portfolio of Drug Development Candidates and Files New Provisional Patent Application

Enveric Biosciences Files Portfolio of Patent Applications for Tryptamine-Based Molecules

Enveric Biosciences, Inc. announces development of EV104a and EV104b

Enveric Biosciences, Inc. (NasdaqCM:ENVB) entered into a definitive agreement to acquire MagicMed Industries Inc.

Enveric Biosciences, Inc. announced delayed annual 10-K filing

Enveric Biosciences, Inc. Appoints Dr. Douglas D. Lind to Company's Board of Directors

Enveric Biosciences, Inc. (NasdaqCM:ENVB) completed the acquisition of Exclusive and perpetual license for Diverse Biotech novel molecules from Diverse Biotech, Inc.

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media